HealthDay News — Oral iron supplementation doesn’t improve the exercise capacity of iron-deficient patients with heart failure with reduced left ventricular ejection fraction (HFrEF), according to a study published in the May 16 issue of the Journal of the American Medical Association.

The research included 225 HFrEF patients who received either oral iron polysaccharide (150mg) or a placebo, twice daily for 16 weeks. The measured outcomes were changes in peak oxygen uptake and 6-minute walk distance.

The investigators found that after 4 months, patients who received iron supplementation did not have higher peak oxygen uptake than those receiving placebo. The team also found no significant differences between treatment groups in changes in 6-minute walk distance. 

Related Articles

“Among participants with HFrEF with iron deficiency, high-dose oral iron did not improve exercise capacity over 16 weeks,” the authors write. “These results do not support use of oral iron supplementation in patients with HFrEF.”

Abstract/Full Text (subscription or payment may be required)